Rina-S — Competitive Intelligence Brief

Rina-S (Rina-S) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bispecific antibody. Area: Oncology.

phase 3 Bispecific antibody Oncology Small molecule

Target snapshot

Rina-S (Rina-S) — Genmab. Rina-S is a bispecific antibody that simultaneously engages two immune checkpoints to enhance T-cell activation and anti-tumor immunity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rina-S TARGET	Rina-S	Genmab	phase 3	Bispecific antibody
Elrexfio	Elranatamab	Pfizer	marketed	Bispecific antibody	BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells	2023-01-01
Elrexfio	elranatamab	Pfizer	marketed	Bispecific antibody	BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells	2023-01-01
Elrantamab	elrantamab	Pfizer	marketed	Bispecific Antibody	BCMA (B-cell maturation antigen)
BAT1706	BAT1706	Bio-Thera Solutions	phase 3	Bispecific antibody; PD-1/TGF-β inhibitor	PD-1 and TGF-β
AK104(SC)	AK104(SC)	Akeso	phase 3	Bispecific antibody; PD-1/TIM-3 checkpoint inhibitor	PD-1; TIM-3
TAR-210	TAR-210	Janssen Research & Development, LLC	phase 3	Bispecific antibody	PD-1 and LAG-3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bispecific antibody class)

1. Shanghai Miracogen Inc. · 3 drugs in this class
2. Atom Therapeutics Co., Ltd · 2 drugs in this class
3. Pfizer · 2 drugs in this class
4. Allergan · 1 drug in this class
5. AstraZeneca · 1 drug in this class
6. BioNTech SE · 1 drug in this class
7. DualityBio Inc. · 1 drug in this class
8. Coherus Oncology, Inc. · 1 drug in this class
9. Genmab · 1 drug in this class
10. Amgen · 1 drug in this class